Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD)
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-…

Rationale: The IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease
Treatment) trial demonstrated a significant reduction in all-cause mortality (ACM) risk with …

Background Combination long-acting bronchodilator therapy may be more effective than
long-acting bronchodilator monotherapy in COPD. Our objectives were to compare the efficacy …

Background Once-daily combination treatment is an attractive maintenance therapy for
COPD. However, the dose of inhaled corticosteroid to use in a once-daily combination is …

Rationale: Inhaled corticosteroids have been shown to decrease exacerbations in patients
with moderate to severe chronic obstructive pulmonary disease (COPD). Their effects in …

Purpose Dual therapy with bronchodilators of different pharmacological classes may produce
greater lung function improvements than either drug alone. However, the relationship …

Rationale: Many patients with chronic obstructive pulmonary disease (COPD) have an
accelerated loss of lung function. It is unclear whether drug treatment can modify this in patients …

Rationale Pneumonia risk with inhaled corticosteroid use in chronic obstructive pulmonary
disease (COPD) has not been thoroughly assessed in patients with moderate airflow limitation…

Rationale: In the IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease
Treatment) trial, fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) significantly …

IMPACT, a 52-week, randomised, double-blind trial, assessed the efficacy and safety of
fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI or UMEC/VI …